Drug Trial Radar · NCT02121795
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Last checked: Nov 20, 2026Latest source record: Mar 12, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
668
Actual
Start
May 6, 2014
Primary completion
Aug 12, 2015
Study completion Mar 1, 2019
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Apr 24, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy of switching from emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) fixed dose combination (FDC) to emtricitabine/tenofovir alafenamide (F/TAF) FDC in HIV-1 positive participants who are virologically suppressed on regimens containing FTC/TDF. This study will consist of a 96 week double-blind treatment period. After Week 96, all participants will continue on blinded study drug treatment and attend visits every 12 weeks until treatment assignments are unblinded. All participants will return for an unblinding visit and will be given the option to receive open-label F/TAF and attend visits every 12 weeks until F/TAF is commercially available, or the sponsor terminates the F/TAF clinical development program.
Conditions
- HIV-1 Infection
Interventions
FTC/TDFDrug
200/300 mg FDC tablets administered orally once daily
F/TAFDrug
Tablets administered orally once daily
Allowed third antiretroviral agentDrug
An allowed third antiretroviral agent of the participant's pre-existing regimen may include one of the following: ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted lopinavir (LPV/r), ritonavir-boosted darunavir (DRV/r), efavirenz (EFV; Sustiva®), rilpivirine (RPV; Edurant®), nevirapine (NVP;Viramune®), raltegravir (RAL; Isentress®), dolutegravir (DTG;Tivicay®), and maraviroc (MVC; Selzentry®).
FTC/TDF PlaceboDrug
Tablets administered orally once daily
F/TAF PlaceboDrug
Tablets administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA Snapshot AnalysisTime frame: Week 48
Locations
78 sites in 7 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Spectrum Medical Group
Phoenix, Arizona
Pacific Oaks Medical Group
Beverly Hills, California
Kaiser Permanente
Hayward, California
Tarrant County ID Associates
Los Angeles, California
Southern California Men's Medical Group
Los Angeles, California
Highland Hospital - Alameda Health System (formerly Alameda County medical Center)
Oakland, California
Kaiser Permanente Sacramento Medical Center
Sacramento, California
La Playa Medical Group and Clinical Research
San Diego, California
Kaiser Permanente Medical Group San Francisco
San Francisco, California
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, California
Kaiser Permanente Colorado
Denver, Colorado
National Jewish Health
Denver, Colorado
Apex Research LLC
Denver, Colorado
Dupont Circle Physician's Group
Washington D.C., District of Columbia
Whitman-Walker Health
Washington D.C., District of Columbia
Capital Medical Associates
Washington D.C., District of Columbia
Medical Faculty Associates
Washington D.C., District of Columbia
TheraFirst Medical Center
Fort Lauderdale, Florida
Gary J. Richmond,M.D.,P.A.
Fort Lauderdale, Florida
Midway Immunology and Research Center
Ft. Pierce, Florida
Tarrant County Infectious Disease Associates
Miami, Florida
AIDS Healthcare Foundation
Miami Beach, Florida
Orlando Immunology Center
Orlando, Florida
AIDS Healthcare Foundation
Tampa, Florida
AIDS Research & Treatment Center of the Treasure Coast
Vero Beach, Florida
Triple O Research Institute PA
West Palm Beach, Florida
Atlanta ID Group
Atlanta, Georgia
AIDS Research Consortium of Atlanta
Atlanta, Georgia
Mercer University School of Medicine
Macon, Georgia
Community Research Initiative of New England
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
Be Well Medical Center
Berkley, Michigan
Hennepin County Medical Center
Minneapolis, Minnesota
The Kc Care Clinic Site 5580
Kansas City, Missouri
St. Louis University
St Louis, Missouri
Southampton Healthcare, Inc.
St Louis, Missouri
Prime Healthcare Services - St Michael's LLC d/b/a Saint Michael's Medical Center
Newark, New Jersey
South Jersey Infectious Disease
Somers Point, New Jersey
Southwest CARE Center
Santa Fe, New Mexico
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.